Cargando…

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

BACKGROUND: Hydroxyurea (HU) is an immunomodulatory agent that has been documented to enhance the antiretroviral activity of nucleoside reverse transcriptase inhibitors, such as abacavir (ABC) and didanosine (ddI), and would be expected to improve virologic efficacy. METHODS: A 48-week, phase IV, mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swindells, Susan, Cohen, Calvin J, Berger, Daniel S, Tashima, Karen T, Liao, Qiming, Pobiner, Bonnie F, Snidow, Jerry W, Pakes, Gary E, Hernandez, Jaime E
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1090576/ https://www.ncbi.nlm.nih.gov/pubmed/15819974 http://dx.doi.org/10.1186/1471-2334-5-23

Ejemplares similares

High-Level Cross-Resistance to Didanosine Observed in South African Children Failing an Abacavir- or Stavudine-Based 1(st)-Line Regimen
por: Steegen, Kim, et al.
Publicado: (2014)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
por: Keiser, Philip H, et al.
Publicado: (2005)

Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal
por: Canestri, Anna, et al.
Publicado: (2007)

Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease
por: Rabie, Amgad M.
Publicado: (2022)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir.
por: Bawdon, R E
Publicado: (1998)

Bioretrosynthetic construction of a didanosine biosynthetic pathway
por: Birmingham, William R., et al.
Publicado: (2014)

A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals
por: Moyle, Graeme J., et al.
Publicado: (2015)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Analysis of in vivo absorption of didanosine tablets in male adult dogs by HPLC
por: Severino, Patrícia, et al.
Publicado: (2012)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America
por: Caro-Vega, Yanink, et al.
Publicado: (2018)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
por: Macías, J, et al.
Publicado: (2010)

A Case of Non-Cirrhotic Portal Hypertension Associated With Chronic Didanosine Therapy
por: Stotts, Matthew, et al.
Publicado: (2015)

Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial
por: Achhra, Amit C., et al.
Publicado: (2014)

Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014)

Preparation of gastro-resistant pellets containing chitosan microspheres for improvement of oral didanosine bioavailability
por: Severino, Patrícia, et al.
Publicado: (2012)

Portal Hypertension Due to Hepatoportal Sclerosis in an HIV-Positive Patient Secondary to Didanosine Use
por: Phrathep, Davong D, et al.
Publicado: (2023)

Evidence-based Medicine and Mechanistic Evidence: The Case of the Failed Rollout of Efavirenz in Zimbabwe
por: Park, Andrew, et al.
Publicado: (2023)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
por: Mastan, SK, et al.
Publicado: (2009)

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
por: Squires, Kathleen E, et al.
Publicado: (2017)

A case of nodular regenerative hyperplasia in a patient who had been taking didanosine
por: Jackson, C, et al.
Publicado: (2010)

Scoring Methods for Building Genotypic Scores: An Application to Didanosine Resistance in a Large Derivation Set
por: Houssaini, Allal, et al.
Publicado: (2013)

Insulin resistance in people living with HIV is associated with exposure to thymidine analogues and/or didanosine and prior immunodeficiency
por: Høgh, Julie, et al.
Publicado: (2022)

Efavirenz Conceptions and Regimen Management in a Prospective Cohort of Women on Antiretroviral Therapy
por: Schwartz, Sheree, et al.
Publicado: (2012)

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
por: Tebas, Pablo, et al.
Publicado: (2015)

Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2012)

Abacavir-induced liver toxicity
por: Pezzani, Maria Diletta, et al.
Publicado: (2016)

Toxic intracellular anabolite levels of tenofovir and didanosine causing a steep CD4-cell decline
por: de Jong, E, et al.
Publicado: (2010)

Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data
por: Alakwaa, Fadhl M.
Publicado: (2020)

Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells
por: Hecht, Markus, et al.
Publicado: (2015)

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
por: Kumar, Princy, et al.
Publicado: (2013)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2013)

Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens
por: Norwood, Jamison, et al.
Publicado: (2017)

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure
por: Stainsby, Chris M., et al.
Publicado: (2018)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
por: Rutherford, George W., et al.
Publicado: (2016)

A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people
por: Schouten, Jeffrey T, et al.
Publicado: (2006)

Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011–2012
por: Galindo, Jaime, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9op6cf81am80n0mdv381ihkvlm